Libtayo's approval for high-risk cutaneous squamous cell carcinoma offers a new immunotherapy option, targeting PD-1 ...

Sanofi and Regeneron’s Dupixent approved in Japan for children aged 6 to 11 years with bronchial asthmaApproval based on global phase 3 program ...

Inflammation that develops in chronic obstructive pulmonary disorder stems from different causes. A new regulatory decision in Europe makes Sanofi and Regeneron Pharmaceuticals drug Dupixent the first ...

Approval based on global Phase 3 program in children demonstrating Dupixent significantly reduced exacerbations (by 54% to 65%) and improved lung ...

Sanofi has announced that Paul Hudson, CEO, will be in attendance at the 44 th annual JP Morgan Healthcare Conference in San ...

Sanofi said its dupixent drug achieved significant improvements for the treatment of two skin diseases. The French pharmaceutical company said Wednesday that the drug met the primary and all key ...

Sanofi SAN posted first-quarter results largely in line with our projections, and we don’t expect any major changes to the firm’s fair value estimate. The stock looks undervalued with the market not ...

Regeneron is set for a turnaround as Dupixent and Libtayo drive growth, and 2026 pipeline catalysts may boost revenue. See why REGN stock is a strong buy.

Now, the company will aim to show the drug helps patients with eczema and asthma in larger, placebo-controlled trial.